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Background
In the vasculature, nitric oxide (NO) binds and activates
smooth muscle soluble guanylate cyclase (sGC), leading to
increased intracellular cGMP, which triggers smooth mus-
cle relaxation and vasodilation. sGC stimulators are a class
of small molecule allosteric modulators, which stimulate
cGMP production independently of NO but also act in
synergy with NO. Evidence to date suggests that sGC sti-
mulators may be balanced vasodilators, meaning that they
elicit vasorelaxation in both the arterial and venous vascu-
lature; however, there have been conflicting reports [1,2].
Our approach to developing a better understanding of the
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arterio/venoselectivity of sGC stimulators was to measure
cGMP concentrations in arteries, veins, plasma, and other
tissues of rats orally administered with one of our sGC
stimulators (MM-46446 or MM-46805) at a pharmacolo-
gically active dose. Results were treated with either vehicle
or an sGC stimulator and cyclic GMP levels were mea-
sured utilizing an extraction method paired with a sensi-
tive LC/MS-MS detection method (LLOQ = 0.3 nmol).
This cGMP quantitation method is linear from 0.3 – 2,890
nmol with no need for either dilutions or derivatizations,
unlike current ELISA based methods that are linear from
0.2 – 3 nmol and require acetylation plus sample dilutions.
Using this cGMP detection method, we were able to deter-
mine that basal cGMP levels appear higher in the aorta
when compared to the pulmonary vein, 16.4 nmol/g ver-
sus 4.64 nmol/g, respectively. Upon treatment with either
of the two sGC stimulators, aorta cGMP levels increased
28.3 and 11.9-fold, respectively, and pulmonary vein
cGMP levels increased 20.0 and 11.1-fold, respectively
(Figure 1).
Conclusion
The current study shows that our sGC stimulators are
able to increase cGMP levels in both the rat aorta and
pulmonary vein and indicates the potential for sGC sti-
mulators to act as balanced vasodilators.
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